Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 2/20 | 0.46 |
| ▸ | FEN1 | P39748 | 13/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 13/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1886975 | 0.80 | FEN1 (0.47) | MPLFEN1ALOX5APIDO1 | |
| SCHEMBL1888242 | 0.79 | FEN1 (0.49) | MPLFEN1ALOX5AP | |
| SCHEMBL1891905 | 0.78 | HSD11B1 (0.50) | MPLFEN1ALOX5APHSD11B1CYP11B1 | |
| SCHEMBL1885931 | 0.76 | FEN1 (0.46) | MPLFEN1ALOX5AP | |
| SCHEMBL27805538 | 0.76 | FEN1 (0.44) | MPLFEN1ALOX5AP | |
| SCHEMBL1884677 | 0.75 | ALOX5AP (0.47) | MPLFEN1ALOX5AP | |
| SCHEMBL1894022 | 0.75 | RECQL (0.47) | MPLFEN1ALOX5AP | |
| SCHEMBL1656041 | 0.75 | ALOX5AP (0.49) | FEN1ALOX5AP | |
| SCHEMBL2390339 | 0.74 | ALOX5AP (0.40) | MPLFEN1ALOX5APIDO1 | |
| SCHEMBL2308521 | 0.74 | L3MBTL1 (0.47) | MPLFEN1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105543-A1 | NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2011-05-05 | — | — | US | disclosed |
| EP-2262767-A1 | NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NeuroSearch A/S (DK) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009112461-A1 | NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105543-A1 | NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA5, CHRNA3, CHRM3 | MPL 4052/4885FEN1 4851/4885ALOX5AP 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.